Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

297463 open-label, multicenter, randomized Phase 2 study of ATR inhibitor tuvusertib + PARP inhibitor niraparib or ATM inhibitor lartesertib in participants with BRCA mutant and/or HRD-positive epithelial ovarian cancer progressing on prior PARP therapy.


Collapse Overview 
Collapse sponsor award id
MS201924_0002


Collapse Biography 

Collapse Time 
Collapse start date
2024-09-30

Collapse end date
2034-09-29